What the FDA labels say about taking them together
Pentoxifylline and repaglinide
Repaglinide's FDA label of May 2, 2025 names pentoxifylline in its drug interactions section; the pentoxifylline label PlainMeds reads does not name repaglinide. The repaglinide label: “… monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.”
Check it at the source: the pentoxifylline FDA label on DailyMed (effective May 15, 2026, Rising Pharma Holdings, Inc.); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).
What does the pentoxifylline label say about repaglinide?
Pentoxifylline's label (effective May 15, 2026) does not name repaglinide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pentoxifylline), Rising Pharma Holdings, Inc., effective May 15, 2026 (SPL set cd840a2c-2a0e-4b2b-84ff-a0406bb6fa37), via openFDA; the full label on DailyMed
What does the repaglinide label say about pentoxifylline?
Repaglinide label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co-administered. Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.
Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pentoxifylline | Repaglinide | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.227 per tablet 400 mg tablet | $0.0987 per tablet 1 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once